CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of gastrointestinal (GI) cancers.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with GI cancers.
  
  LEARNING OBJECTIVES

  • Apply available research data to the therapeutic and supportive care of patients with colorectal cancer (CRC), gastric cancer and hepatocellular carcinoma (HCC).
  • Communicate to patients with advanced HCC the benefits and risks of approved multikinase inhibitor regimens and emerging approaches with combined immune checkpoint inhibitors and anti-angiogenic agents.
  • Recognize the significance of biomarker status (eg, microsatellite instability, mismatch repair deficiency, PD-L1 expression, BRAF mutation) and tumor location in patients with CRC or gastric or gastroesophageal junction cancer, and use this information to counsel them about evidence-based options for systemic treatment.
  • Describe the clinical indications, benefits and toxicities associated with current and recently approved systemic therapies in the management of metastatic CRC (mCRC).
  • Appraise the rationale for and clinical data with immune checkpoint inhibitors and novel antimetabolites in the treatment of gastroesophageal cancer.
  • Develop a plan to manage the side effects associated with available and recently approved systemic therapies in order to support quality of life and continuation of treatment for patients with GI cancers.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENTS
  CNE credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  CNE credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  This CNE activity consists of an audio component.
  CNE credit is no longer available for this issue
  
  This CNE activity consists of a video component.
  CNE credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Melony Avella-Howell, NP
  Aurora, Colorado
  
  No financial interests or affiliations to disclose.
  
  Wells A Messersmith, MD
  Professor and Head, Division of Medical Oncology
  Associate Director for Translational Research
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Contracted Research: Aduro Biotech, ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, D3 Pharma, Gossamer Bio, Immunomedics Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics, QED Therapeutics.
  
  Philip A Philip, MD, PhD, FRCP
  Kathryn Cramer Endowed Chair in Cancer Research
  Professor of Oncology and Pharmacology
  Leader, GI and Neuroendocrine Oncology
  Karmanos Cancer Institute
  Wayne State University
  Detroit, Michigan
  
  No financial interests or affiliations to disclose.
  
  Tammy Triglianos, RN, MS, ANP-BC, AOCNP
  GI Oncology Nurse Practitioner
  Lineberger Comprehensive Cancer Center
  The University of North Carolina Division of Oncology
  Department of Medicine, University of North Carolina
  Chapel Hill, North Carolina
  
  No financial interests or affiliations to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc.
  
  RTP CNE (NCPD) PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Genentech, a member of the Roche Group, and Taiho Oncology Inc.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: July 2020
  Expiration date: July 2021
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.